Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 273 shares of the firm's stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the transaction, the insider now owns 7,507 shares in the company, valued at approximately $1,055,108.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Ingrid Delaet also recently made the following trade(s):
- On Thursday, March 21st, Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00.
- On Monday, March 11th, Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.00, for a total value of $28,000.00.
- On Friday, March 8th, Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $140.03, for a total value of $252,054.00.
- On Thursday, February 29th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.51, for a total transaction of $36,994.23.
Neurocrine Biosciences Stock Performance
Top 5 AI Stocks to Buy for 2024
From Market Moving Trends | Ad
5 Best AI Stocks to Invest In
Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
NASDAQ:NBIX opened at $139.50 on Thursday. The company has a market cap of $14.04 billion, a price-to-earnings ratio of 38.30 and a beta of 0.28. The stock's fifty day moving average price is $137.72 and its two-hundred day moving average price is $129.51. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.88 earnings per share. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current fiscal year.
Hedge Funds Weigh In On Neurocrine Biosciences
Several large investors have recently bought and sold shares of NBIX. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Neurocrine Biosciences by 34.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,194 shares of the company's stock valued at $7,612,000 after purchasing an additional 14,015 shares in the last quarter. Fortis Capital Advisors LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at $584,000. State Board of Administration of Florida Retirement System raised its stake in Neurocrine Biosciences by 2.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 109,446 shares of the company's stock worth $15,095,000 after buying an additional 2,153 shares during the period. Motley Fool Asset Management LLC lifted its holdings in Neurocrine Biosciences by 337.9% during the first quarter. Motley Fool Asset Management LLC now owns 8,188 shares of the company's stock worth $1,129,000 after acquiring an additional 6,318 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in Neurocrine Biosciences by 3.3% in the first quarter. ProShare Advisors LLC now owns 11,829 shares of the company's stock valued at $1,631,000 after acquiring an additional 383 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. Guggenheim increased their target price on Neurocrine Biosciences from $164.00 to $170.00 and gave the company a "buy" rating in a report on Thursday, May 2nd. Canaccord Genuity Group lifted their price target on Neurocrine Biosciences from $154.00 to $164.00 and gave the company a "buy" rating in a report on Thursday, May 2nd. Oppenheimer increased their price objective on Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an "outperform" rating in a research note on Thursday, May 2nd. Finally, Wedbush reaffirmed an "outperform" rating and set a $147.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $147.88.
Get Our Latest Analysis on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
